thalidomide has been researched along with Histiocytosis, Langerhans-Cell in 34 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Histiocytosis, Langerhans-Cell: A group of disorders resulting from the abnormal proliferation of and tissue infiltration by LANGERHANS CELLS which can be detected by their characteristic Birbeck granules (X bodies), or by monoclonal antibody staining for their surface CD1 ANTIGENS. Langerhans-cell granulomatosis can involve a single organ, or can be a systemic disorder.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We showed an effect of lenalidomide in Langerhans cell histiocytosis and in Castleman disease." | 8.88 | [The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis]. ( Adam, Z; Hájek, R; Koukalová, R; Král, Z; Krejčí, M; Mayer, J; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L, 2012) |
| "We showed an effect of lenalidomide in Langerhans cell histiocytosis and in Castleman disease." | 4.88 | [The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis]. ( Adam, Z; Hájek, R; Koukalová, R; Král, Z; Krejčí, M; Mayer, J; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L, 2012) |
| " Thalidomide (N-phtalimidoglutarimide), initially used as a tranquilizer, has recently been used in the management of several inflammatory skin diseases." | 3.72 | Successful treatment of cutaneous langerhans cell histiocytosis with thalidomide. ( Elsner, P; Kaatz, M; Sander, CS, 2004) |
| "Thalidomide is an effective therapy for some LR patients with LCH, but showed no significant responses in HR patients." | 2.73 | A phase II trial using thalidomide for Langerhans cell histiocytosis. ( Kozinetz, CA; McClain, KL, 2007) |
| "Thalidomide was first introduced in the 1950s as a sedative but was quickly removed from the market after it was linked to cases of severe birth defects." | 2.43 | Thalidomide: dermatological indications, mechanisms of action and side-effects. ( Hsu, S; Huang, DB; Pang, KR; Tyring, SK; Wu, JJ, 2005) |
| "Thalidomide has proven useful for patients with Langerhans cell histiocytosis of the skin and/or bone." | 2.43 | Drug therapy for the treatment of Langerhans cell histiocytosis. ( McClain, KL, 2005) |
| " All four children completed the protocol without any significant adverse effects and remain in complete and durable remission 15-18 months posttreatment." | 1.46 | Excellent remission rates with limited toxicity in relapsed/refractory Langerhans cell histiocytosis with pulse dexamethasone and lenalidomide in children. ( Bakane, A; Raj, R; Ramachandrakurup, S; Subburaj, D; Uppuluri, R, 2017) |
| "Refractory/relapsed Langerhans cell histiocytosis (LCH) has a difficult course with a guarded prognosis." | 1.46 | Successful Treatment of Refractory Langerhans Cell Histiocytosis of the Choroid Plexus in a Child With Pulse Dexamethasone and Lenalidomide. ( Bakane, A; Balaji, R; Raj, R; Ramachandrakurup, S; Subburaj, D; Uppuluri, R, 2017) |
| "Adult Langerhans cell histiocytosis (LCH) usually follows a favorable course." | 1.38 | [Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transp ( Adam, Z; Adamová, Z; Brejcha, M; Hájek, R; Kodet, R; Koukalová, R; Krejčí, M; Mayer, J; Moulis, M; Nebeský, T; Pour, L; Rehák, Z; Szturz, P; Zahradová, L, 2012) |
| "Thalidomide is an immunomodulator agent of inflammatory cytokines including TNF-alpha." | 1.33 | A case of disseminated Langerhans' cell histiocytosis treated with thalidomide. ( Castoldi, G; Fraulini, C; Galeotti, R; Mauro, E; Rigolin, GM; Spanedda, R, 2005) |
| "Thalidomide treatment is an adequate therapeutic measure in adult Langerhans cell histiocytosis, which is rare and difficult to treat." | 1.33 | [Thalidomide in adult multisystem Langerhans cell histiocytosis: a case report]. ( Alioua, Z; Frikh, R; Ghfir, M; Hjira, N; Oumakhir, S; Rimani, M; Sedrati, O, 2006) |
| "Adult onset Langerhans cell histiocytosis is uncommon." | 1.31 | Langerhans' cell histiocytosis. ( Ehsani, A; Hosseini, M; Mortazavi, H; Namazi, MR, 2002) |
| "We report one case of Langerhans cell histiocytosis in a 33-year-old woman with resistant vulvar involvement whose cutaneous lesions improved with thalidomide." | 1.30 | [Langerhans histiocytosis in adults: cutaneous and mucous lesion regression after treatment with thalidomide]. ( Blot, E; Boullié, MC; Cailleux, N; Courtois, H; Courville, P; Lair, G; Lauret, P; Lévesque, H; Marie, I, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (17.65) | 18.2507 |
| 2000's | 15 (44.12) | 29.6817 |
| 2010's | 12 (35.29) | 24.3611 |
| 2020's | 1 (2.94) | 2.80 |
| Authors | Studies |
|---|---|
| Wang, JN | 1 |
| Liu, T | 1 |
| Zhao, AL | 1 |
| Pan, BJ | 1 |
| Sun, J | 1 |
| Li, J | 1 |
| Zhou, DB | 1 |
| Cao, XX | 1 |
| Duan, MH | 1 |
| Roider, E | 1 |
| Signer, C | 1 |
| Fehrenbacher, B | 1 |
| Metzler, G | 2 |
| Schaller, M | 2 |
| Kamarachev, J | 1 |
| Kerl, K | 1 |
| Balabanov, S | 1 |
| Jochum, W | 1 |
| Hoetzenecker, W | 1 |
| Cozzio, A | 1 |
| French, LE | 1 |
| Dummer, R | 1 |
| Guenova, E | 1 |
| Minkov, M | 1 |
| Wu, C | 1 |
| Uppuluri, R | 2 |
| Ramachandrakurup, S | 2 |
| Subburaj, D | 2 |
| Bakane, A | 2 |
| Raj, R | 2 |
| Ruiz Beguerie, J | 1 |
| Fernández, J | 1 |
| Stringa, MF | 1 |
| Anaya, J | 1 |
| Balaji, R | 1 |
| Ng-Cheng-Hin, B | 1 |
| O'Hanlon-Brown, C | 1 |
| Alifrangis, C | 1 |
| Waxman, J | 1 |
| Szturz, P | 3 |
| Adam, Z | 3 |
| Rehák, Z | 3 |
| Koukalová, R | 3 |
| Slaisová, R | 1 |
| Stehlíková, O | 1 |
| Chovancová, J | 1 |
| Klabusay, M | 1 |
| Krejčí, M | 3 |
| Pour, L | 3 |
| Hájek, R | 3 |
| Mayer, J | 3 |
| Zahradová, L | 2 |
| Moulis, M | 1 |
| Kodet, R | 1 |
| Nebeský, T | 2 |
| Brejcha, M | 1 |
| Adamová, Z | 1 |
| Alexandrescu, S | 1 |
| Tatevian, N | 1 |
| Czerniak, BA | 1 |
| Covinsky, MH | 1 |
| Burns, NK | 1 |
| Brown, RE | 1 |
| Král, Z | 1 |
| Li, KY | 1 |
| Hu, YM | 1 |
| Lü, JB | 1 |
| Claudon, A | 1 |
| Dietemann, JL | 1 |
| Hamman De Compte, A | 1 |
| Hassler, P | 1 |
| Kolde, G | 1 |
| Schulze, P | 1 |
| Sterry, W | 1 |
| Mortazavi, H | 1 |
| Ehsani, A | 1 |
| Namazi, MR | 1 |
| Hosseini, M | 1 |
| Santillan, A | 1 |
| Montero, AJ | 1 |
| Kavanagh, JJ | 1 |
| Liu, J | 1 |
| Ramirez, PT | 1 |
| Deng, YJ | 1 |
| Hao, F | 1 |
| Zhou, CL | 1 |
| Sun, RS | 1 |
| Xiang, MM | 1 |
| Wang, JW | 1 |
| Zhong, BY | 1 |
| Ye, QY | 1 |
| Liu, RQ | 1 |
| Sander, CS | 1 |
| Kaatz, M | 1 |
| Elsner, P | 1 |
| Mauro, E | 1 |
| Fraulini, C | 1 |
| Rigolin, GM | 1 |
| Galeotti, R | 1 |
| Spanedda, R | 1 |
| Castoldi, G | 1 |
| Wu, JJ | 1 |
| Huang, DB | 1 |
| Pang, KR | 1 |
| Hsu, S | 1 |
| Tyring, SK | 1 |
| McClain, KL | 2 |
| Kozinetz, CA | 1 |
| Alioua, Z | 1 |
| Hjira, N | 1 |
| Oumakhir, S | 1 |
| Frikh, R | 1 |
| Ghfir, M | 1 |
| Rimani, M | 1 |
| Sedrati, O | 1 |
| Moravvej, H | 1 |
| Yousefi, M | 1 |
| Barikbin, B | 1 |
| Broekaert, SM | 1 |
| Burgdorf, W | 1 |
| Röcken, M | 1 |
| Dallafior, S | 1 |
| Pugin, P | 1 |
| Cerny, T | 1 |
| Betticher, D | 1 |
| Saurat, JH | 1 |
| Hauser, C | 1 |
| Meunier, L | 1 |
| Marck, Y | 1 |
| Ribeyre, C | 1 |
| Meynadier, J | 1 |
| Thomas, L | 1 |
| Ducros, B | 1 |
| Secchi, T | 1 |
| Balme, B | 1 |
| Moulin, G | 1 |
| Misery, L | 1 |
| Larbre, B | 1 |
| Lyonnet, S | 1 |
| Faure, M | 1 |
| Thivolet, J | 1 |
| Lair, G | 1 |
| Marie, I | 1 |
| Cailleux, N | 1 |
| Blot, E | 1 |
| Boullié, MC | 1 |
| Courville, P | 1 |
| Lauret, P | 1 |
| Lévesque, H | 1 |
| Courtois, H | 1 |
| Moraes, M | 1 |
| Russo, G | 1 |
| Pouaha, J | 1 |
| Martin, S | 1 |
| Trechot, P | 1 |
| Truchetet, F | 1 |
| Barbaud, A | 1 |
| Schmutz, JL | 1 |
| Bensaid, P | 1 |
| Machet, L | 1 |
| Vaillant, L | 1 |
| Machet, MC | 1 |
| Scotto, B | 1 |
| Lorette, G | 1 |
9 reviews available for thalidomide and Histiocytosis, Langerhans-Cell
| Article | Year |
|---|---|
An update on the treatment of pediatric-onset Langerhans cell histiocytosis through pharmacotherapy.
Topics: Antineoplastic Agents; Central Nervous System; Child; Clinical Trials as Topic; Drug Therapy, Combin | 2018 |
Langerhans cell histiocytosis: old disease new treatment.
Topics: Cladribine; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Thalidomide | 2011 |
[The effect of lenalidomide on rare blood disorders: Langerhans cell histiocytosis, multicentric Castleman disease, POEMS syndrome, Erdheim-Chester disease and angiomatosis].
Topics: Aged; Castleman Disease; Erdheim-Chester Disease; Female; Histiocytosis, Langerhans-Cell; Humans; Le | 2012 |
Vulvar Langerhans cell histiocytosis: a case report and review of the literature.
Topics: Adult; Combined Modality Therapy; Female; Histiocytosis, Langerhans-Cell; Humans; Thalidomide; Vulva | 2003 |
Thalidomide: dermatological indications, mechanisms of action and side-effects.
Topics: Adult; Behcet Syndrome; Dermatologic Agents; Erythema; Graft vs Host Disease; Histiocytosis, Langerh | 2005 |
Drug therapy for the treatment of Langerhans cell histiocytosis.
Topics: Anti-Inflammatory Agents; Antimetabolites; Brain Diseases; Cell Proliferation; Cladribine; Cytarabin | 2005 |
Successful treatment of adult's Langerhans cell histiocytosis with thalidomide. Report of two cases and literature review.
Topics: Adolescent; Anus Diseases; Female; Histiocytosis, Langerhans-Cell; Humans; Middle Aged; Skin; Thalid | 1993 |
Thalidomide and its dermatologic uses.
Topics: Acquired Immunodeficiency Syndrome; Behcet Syndrome; Dermatologic Agents; Erythema Nodosum; Facial D | 2001 |
[Langerhans-cell histiocytosis in the adult: regressive parotid involvement following thalidomide therapy].
Topics: Adult; Female; Histiocytosis, Langerhans-Cell; Humans; Intertrigo; Parotid Diseases; Pregnancy; Preg | 1992 |
2 trials available for thalidomide and Histiocytosis, Langerhans-Cell
| Article | Year |
|---|---|
Phase 2 study of oral thalidomide-cyclophosphamide-dexamethasone for recurrent/refractory adult Langerhans cell histiocytosis.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Dexamethasone; Histiocytosi | 2022 |
A phase II trial using thalidomide for Langerhans cell histiocytosis.
Topics: Adolescent; Adult; Child; Child, Preschool; Disease-Free Survival; Female; Histiocytosis, Langerhans | 2007 |
23 other studies available for thalidomide and Histiocytosis, Langerhans-Cell
| Article | Year |
|---|---|
Individualized treatment approaches for Langerhans cell histiocytosis.
Topics: Adrenal Cortex Hormones; Adult; Aged, 80 and over; Azetidines; Bone Diseases; Dermatologic Agents; F | 2018 |
Red plaques and tumors on the vulva.
Topics: Asymptomatic Diseases; Female; Glucocorticoids; Histiocytosis, Langerhans-Cell; Humans; Immunosuppre | 2019 |
Excellent remission rates with limited toxicity in relapsed/refractory Langerhans cell histiocytosis with pulse dexamethasone and lenalidomide in children.
Topics: Angiogenesis Inhibitors; Anti-Inflammatory Agents; Child, Preschool; Dexamethasone; Drug Resistance; | 2017 |
Vulvar Langerhans cell histiocytosis and thalidomide: an effective treatment option.
Topics: Female; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Middle Aged; Thalidomide; | 2017 |
Successful Treatment of Refractory Langerhans Cell Histiocytosis of the Choroid Plexus in a Child With Pulse Dexamethasone and Lenalidomide.
Topics: Choroid Plexus; Cladribine; Cytarabine; Dexamethasone; Diabetes Insipidus; Drug Resistance; Histiocy | 2017 |
Lenalidomide proved effective in multisystem Langerhans cell histiocytosis.
Topics: Adult; Antineoplastic Agents; Histiocytosis, Langerhans-Cell; Humans; Lenalidomide; Male; Neoplasm R | 2012 |
[Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transp
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cladribine; Combined Modality The | 2012 |
Morphoproteomics provides support for TGF-β pathway signaling in the osteoclastogenesis and immune dysregulation of osteolytic Langerhans cell histiocytosis.
Topics: Biomarkers; Cell Differentiation; Cell Membrane; Cell Nucleus; Child; Child, Preschool; Cytoplasm; F | 2012 |
[Six years relapse-free treatment of a case with Langerhans cell histiocytosis grade III treated with thalidomide and prednisone].
Topics: Administration, Oral; Adolescent; Female; Histiocytosis, Langerhans-Cell; Humans; Lymph Nodes; Predn | 2012 |
[Interest in thalidomide in cutaneo-mucous and hypothalamo-hypophyseal involvement of Langerhans cell histiocytosis].
Topics: Adult; Female; Genital Diseases, Female; Histiocytosis, Langerhans-Cell; Humans; Hypothalamic Diseas | 2002 |
Mixed response to thalidomide therapy in adults: two cases of multisystem Langerhans' cell histiocytosis.
Topics: Administration, Oral; Adult; Anus Diseases; Dose-Response Relationship, Drug; Drug Administration Sc | 2002 |
Langerhans' cell histiocytosis.
Topics: Adult; Histiocytosis, Langerhans-Cell; Humans; Male; Skin Diseases; Thalidomide | 2002 |
Generalized eruptive histiocytosis: a possible therapeutic cure?
Topics: Adult; Dermatologic Agents; Drug Therapy, Combination; Facial Dermatoses; Histiocytosis, Langerhans- | 2004 |
Successful treatment of cutaneous langerhans cell histiocytosis with thalidomide.
Topics: Administration, Oral; Adult; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration S | 2004 |
A case of disseminated Langerhans' cell histiocytosis treated with thalidomide.
Topics: Aged; Female; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Langerhans Cells; Th | 2005 |
[Thalidomide in adult multisystem Langerhans cell histiocytosis: a case report].
Topics: Adult; Female; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Remission Induction | 2006 |
An unusual case of adult disseminated cutaneous Langerhans cell histiocytosis.
Topics: Adult; Antigens, CD1; Biomarkers; Combined Modality Therapy; Cyclosporine; Histiocytosis, Langerhans | 2006 |
Multisystem Langerhans cell histiocytosis: successful treatment with thalidomide.
Topics: Anti-Inflammatory Agents; Central Nervous System Diseases; Female; Histiocytosis, Langerhans-Cell; H | 2007 |
[Successful treatment of a case of cutaneous Langerhans cell granulomatosis with 2-chlorodeoxyadenosine and thalidomide].
Topics: Aged; Cladribine; Drug Therapy, Combination; Female; Histiocytosis, Langerhans-Cell; Humans; Immunos | 1995 |
Adult cutaneous Langerhans cell histiocytosis: remission with thalidomide treatment.
Topics: Aged; Histiocytosis, Langerhans-Cell; Humans; Male; Skin Diseases; Thalidomide | 1995 |
Remission of Langerhans cell histiocytosis with thalidomide treatment.
Topics: Aged; Histiocytosis, Langerhans-Cell; Humans; Male; Thalidomide | 1993 |
[Langerhans histiocytosis in adults: cutaneous and mucous lesion regression after treatment with thalidomide].
Topics: Adult; Dermatologic Agents; Female; Histiocytosis, Langerhans-Cell; Humans; Patient Compliance; Recu | 1998 |
[Thalidomide and thrombosis: three observations].
Topics: Adult; Aged; Behcet Syndrome; Histiocytosis, Langerhans-Cell; Humans; Immunosuppressive Agents; Lupu | 2001 |